Immunotherapy in breast cancer-paving new roads?

Cristina Truica, Allison S. Cleary

Research output: Contribution to journalReview article

Abstract

Significant advances have been made in our understanding of the mechanisms of innate and adaptive immunity and the mechanisms by which tumors escape from the normal process of immune surveillance. However, effectively harnessing the power of the immune system to specifically target the tumor cells has proven quite difficult, in large part due to the fact that tumors are composed of patient’s own cells, expressing antigens recognized as "self" and thus escaping the immune surveillance. For breast cancer treatment, the first successful inroads in immunotherapy came with the introduction of monoclonal antibodies against a membrane receptor for the epidermal growth factor receptor family (HER2). In 1998 the first monoclonal antibody against the Her 2 antigen was approved for clinical use (trastuzumab). Clinical trials combining trastuzumab with various chemotherapy regimens have consistently shown improvement in survival in both metastatic as well as early stage breast cancer. Another promising approach has been the development of anti HER 2 vaccines. More recently the discovery of immune modulating antibodies (checkpoint inhibitors) and their success in the treatment of cancers such as melanoma and renal cell carcinoma has lead to renewed interest in immune therapies in cancer in general and new clinical trials exploring the role of immune therapies in breast cancer.

Original languageEnglish (US)
Pages (from-to)208-216
Number of pages9
JournalCurrent Molecular Pharmacology
Volume9
Issue number3
DOIs
StatePublished - Aug 1 2016

Fingerprint

Immunotherapy
Breast Neoplasms
Neoplasms
Monoclonal Antibodies
Clinical Trials
Tumor Escape
Antigens
Adaptive Immunity
Therapeutics
Renal Cell Carcinoma
Epidermal Growth Factor Receptor
Innate Immunity
Immune System
Melanoma
Vaccines
Drug Therapy
Membranes
Survival
Antibodies
Trastuzumab

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Truica, Cristina ; Cleary, Allison S. / Immunotherapy in breast cancer-paving new roads?. In: Current Molecular Pharmacology. 2016 ; Vol. 9, No. 3. pp. 208-216.
@article{b78926a7c80c420d942413aafa982764,
title = "Immunotherapy in breast cancer-paving new roads?",
abstract = "Significant advances have been made in our understanding of the mechanisms of innate and adaptive immunity and the mechanisms by which tumors escape from the normal process of immune surveillance. However, effectively harnessing the power of the immune system to specifically target the tumor cells has proven quite difficult, in large part due to the fact that tumors are composed of patient’s own cells, expressing antigens recognized as {"}self{"} and thus escaping the immune surveillance. For breast cancer treatment, the first successful inroads in immunotherapy came with the introduction of monoclonal antibodies against a membrane receptor for the epidermal growth factor receptor family (HER2). In 1998 the first monoclonal antibody against the Her 2 antigen was approved for clinical use (trastuzumab). Clinical trials combining trastuzumab with various chemotherapy regimens have consistently shown improvement in survival in both metastatic as well as early stage breast cancer. Another promising approach has been the development of anti HER 2 vaccines. More recently the discovery of immune modulating antibodies (checkpoint inhibitors) and their success in the treatment of cancers such as melanoma and renal cell carcinoma has lead to renewed interest in immune therapies in cancer in general and new clinical trials exploring the role of immune therapies in breast cancer.",
author = "Cristina Truica and Cleary, {Allison S.}",
year = "2016",
month = "8",
day = "1",
doi = "10.2174/1874467208666150716120427",
language = "English (US)",
volume = "9",
pages = "208--216",
journal = "Current Molecular Pharmacology",
issn = "1874-4702",
publisher = "Bentham Science Publishers",
number = "3",

}

Immunotherapy in breast cancer-paving new roads? / Truica, Cristina; Cleary, Allison S.

In: Current Molecular Pharmacology, Vol. 9, No. 3, 01.08.2016, p. 208-216.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Immunotherapy in breast cancer-paving new roads?

AU - Truica, Cristina

AU - Cleary, Allison S.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Significant advances have been made in our understanding of the mechanisms of innate and adaptive immunity and the mechanisms by which tumors escape from the normal process of immune surveillance. However, effectively harnessing the power of the immune system to specifically target the tumor cells has proven quite difficult, in large part due to the fact that tumors are composed of patient’s own cells, expressing antigens recognized as "self" and thus escaping the immune surveillance. For breast cancer treatment, the first successful inroads in immunotherapy came with the introduction of monoclonal antibodies against a membrane receptor for the epidermal growth factor receptor family (HER2). In 1998 the first monoclonal antibody against the Her 2 antigen was approved for clinical use (trastuzumab). Clinical trials combining trastuzumab with various chemotherapy regimens have consistently shown improvement in survival in both metastatic as well as early stage breast cancer. Another promising approach has been the development of anti HER 2 vaccines. More recently the discovery of immune modulating antibodies (checkpoint inhibitors) and their success in the treatment of cancers such as melanoma and renal cell carcinoma has lead to renewed interest in immune therapies in cancer in general and new clinical trials exploring the role of immune therapies in breast cancer.

AB - Significant advances have been made in our understanding of the mechanisms of innate and adaptive immunity and the mechanisms by which tumors escape from the normal process of immune surveillance. However, effectively harnessing the power of the immune system to specifically target the tumor cells has proven quite difficult, in large part due to the fact that tumors are composed of patient’s own cells, expressing antigens recognized as "self" and thus escaping the immune surveillance. For breast cancer treatment, the first successful inroads in immunotherapy came with the introduction of monoclonal antibodies against a membrane receptor for the epidermal growth factor receptor family (HER2). In 1998 the first monoclonal antibody against the Her 2 antigen was approved for clinical use (trastuzumab). Clinical trials combining trastuzumab with various chemotherapy regimens have consistently shown improvement in survival in both metastatic as well as early stage breast cancer. Another promising approach has been the development of anti HER 2 vaccines. More recently the discovery of immune modulating antibodies (checkpoint inhibitors) and their success in the treatment of cancers such as melanoma and renal cell carcinoma has lead to renewed interest in immune therapies in cancer in general and new clinical trials exploring the role of immune therapies in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84989271362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989271362&partnerID=8YFLogxK

U2 - 10.2174/1874467208666150716120427

DO - 10.2174/1874467208666150716120427

M3 - Review article

VL - 9

SP - 208

EP - 216

JO - Current Molecular Pharmacology

JF - Current Molecular Pharmacology

SN - 1874-4702

IS - 3

ER -